genes, respectively. The genes associated with PCDH19-FE were then compared against the 223 genes that exhibit gender bias, identified by comparing the expression profiles of healthy males to those of healthy females. This approach identified 43 gender-biased genes that are associated with PCDH19-FE. To gain some insight into the pathways associated with the gene alterations in PCDH19-FE, the authors examined an annotated list of these genes using the Database for Annotation, Visualization and Integrated Discovery (DAVID) pathway and Ingenuity Pathway Analysis (IPA). These methods identified cell adhesion and integrin-related signaling pathways, consistent with the role of protocadherin 19 as a cell adhesion molecule. However, none of the pathways identified included gender-biased genes.
At this point, the authors had the ingenuity to examine the upstream regulatory elements of the PCDH19-FE associated genes and demonstrated that 22% of them possess progesterone and estrogen regulatory sites. Thus, these steroid hormone regulatory sites may confer gender-specific regulation and be important for PCDH19-FE. Five of these genes (WISP2, OXTR, AKR1C3, APOD, and GRIA1) were validated using reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR). Two of these genes, AKR1C2 and AKR1C3, were of particular interest given their function in neurosteroidogenesis, including the synthesis of allopregnanolone.
Allopregnanolone (3α-hydroxy-5α-pregnan-20-one or 3α,5α-tetrahydroprogesterone) is a neurosteroid derived from progesterone that acts as a positive allosteric modulator at GABA A receptors. Not only can allopregnanolone directly Protocadherin 19 (PCDH19) female limited epilepsy (PCDH19-FE; also known as epilepsy and mental retardation limited to females, EFMR; MIM300088) is an infantile onset epilepsy syndrome with or without intellectual disability (ID) and autism. We investigated transcriptomes of PCDH19-FE female and control primary skin fibroblasts, which are endowed to metabolize neurosteroid hormones. We identified a set of 94 significantly dysregulated genes in PCDH19-FE females. Intriguingly, 43 of the 94 genes (45.7%) showed gender-biased expression; enrichment of such genes was highly significant (P = 2.51E−47, two-tailed Fisher exact test). We further investigated the AKR1C1-3 genes, which encode crucial steroid hormone-metabolizing enzymes whose key products include allopregnanolone and estradiol. Both mRNA and protein levels of AKR1C3 were significantly decreased in PCDH19-FE patients. In agreement with this, the blood levels of allopregnanolone were also (P < 0.01) reduced. In conclusion, we show that the deficiency of neurosteroid allopregnanolone, one of the most potent GABA receptor modulators, may contribute to PCDH19-FE. Overall our findings provide evidence for a role of neurosteroids in epilepsy, ID and autism and create realistic opportunities for targeted therapeutic interventions.
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modulate GABAergic signaling via allosteric modulation, allopregnanolone can also impact GABAergic transmission by altering the expression of specific GABA A receptor subunits. Extrasynaptic GABA A receptors, which mediate tonic GABAergic inhibition, are particularly sensitive to neurosteroid modulation, and actions of allopregnanolone on these receptors are thought to mediate their potent anticonvulsant actions.
The steroid hormone precursor to allopregnanolone, progesterone, has been shown to exert anticonvulsant effects (1), mediated at least in part by the production of neurosteroids (2, 3) . Consistent with their anticonvulsant actions, exogenous allopregnanolone has been shown to exert anticonvulsant actions in numerous animal models of epilepsy (2, 3) . More importantly, allopregnanolone has recently been shown to be beneficial in the treatment of patients with severe status epilepticus (4) (5) (6) . Withdrawal of steroid hormones has been demonstrated to increase seizure susceptibility, in part owing to the reduction in neurosteroid levels and also attributed to alterations in GABA A receptor subunit expression (7) . Interestingly, PCDH19 has been shown to directly interact with at least one GABA A receptor subunit, alpha 1 (8) . However, further studies are required to determine whether PCDH19 plays a role in the regulation of GABA A receptors and whether these interactions may contribute to the pathophysiology of PCDH19-FE. Reductions in the levels of allopregnanolone has also been implicated in a subset of epilepsy in which seizures are aggravated by the menstrual cycle, termed catamenial epilepsy (9) , which can be ameliorated with progesterone treatment (10) . Although the current study focuses on low levels of neurosteroids during early PCDH19-FE development, a similar mechanism for seizure generation has been proposed for neurosteroid withdrawal associated with catamenial epilepsy.
These findings suggest that neurosteroids or compounds targeting their site of action-namely, extrasynaptic GABA A receptors-may be useful for treatment of numerous types of epilepsies, including PCDH19-FE. In fact, an open-label study recently demonstrated the effectiveness of allopregnanolone in the treatment of status epilepticus. A clinical trial has also been initiated testing the use of Ganaxolone, a synthetic analog of allopregnanolone, for the treatment of PCDH19 pediatric epilepsy. One of the benefits of the use of neurosteroids for therapy is that they do not exhibit the development of tolerance (11) , in contrast to benzodiazepines. Refinement of compounds related to neurosteroids to improve the halflife, route of administration, efficacy, and bioavailability will likely have significant therapeutic potential particularly for the epilepsies and perhaps, in particular, PCDH19-FE.
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